Virtus ETF Advisers LLC Inhibrx, Inc. Transaction History

Virtus ETF Advisers LLC

$183 Million
Q1 2024

A detailed history of Virtus ETF Advisers LLC transactions in Inhibrx, Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 3,143 shares of INBX stock, worth $44,536. This represents 0.06% of its overall portfolio holdings.

Number of Shares

3,143

Previous 3,362 6.51%

Holding current value

$44,536

Previous $127,000 14.17%

% of portfolio

0.06%

Previous 0.08%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$32.76 - $39.56 $7,174 - $8,663	-219 Reduced 6.51%	3,143 $109,000
Q4 2023 Feb 15, 2024	SELL	$14.5 - $38.0 $4,582 - $12,008	-316 Reduced 8.59%	3,362 $127,000
Q3 2023 Nov 07, 2023	SELL	$15.75 - $26.31 $5,764 - $9,629	-366 Reduced 9.05%	3,678 $67,000
Q2 2023 Aug 14, 2023	BUY	$16.96 - $27.82 $10,277 - $16,858	606 Added 17.63%	4,044 $104,000
Q1 2023 May 15, 2023	SELL	$18.45 - $27.14 $24,409 - $35,906	-1,323 Reduced 27.79%	3,438 $64,000

Q4 2022 Feb 14, 2023	SELL	$20.18 - $33.33 $151,390 - $250,041	-7,502 Reduced 61.18%	4,761 $117,000
Q3 2022 Nov 14, 2022	BUY	$11.58 - $24.73 $1,053 - $2,250	91 Added 0.75%	12,263 $220,000
Q2 2022 Aug 12, 2022	BUY	$8.52 - $25.26 $69,898 - $207,233	8,204 Added 206.75%	12,172 $138,000
Q1 2022 May 16, 2022	SELL	$19.89 - $43.18 $4,614 - $10,017	-232 Reduced 5.52%	3,968 $88,000
Q4 2021 Feb 14, 2022	SELL	$26.75 - $46.02 $120,241 - $206,859	-4,495 Reduced 51.7%	4,200 $183,000
Q3 2021 Nov 15, 2021	SELL	$25.18 - $37.81 $11,532 - $17,316	-458 Reduced 5.0%	8,695 $290,000
Q2 2021 Aug 10, 2021	BUY	$14.69 - $27.52 $27,690 - $51,875	1,885 Added 25.94%	9,153 $252,000
Q1 2021 May 17, 2021	BUY	$16.27 - $41.26 $2,196 - $5,570	135 Added 1.89%	7,268 $146,000
Q4 2020 Feb 12, 2021	BUY	$15.96 - $50.0 $113,842 - $356,650	7,133 New	7,133 $235,000

Others Institutions Holding INBX

# of Institutions

132

Shares Held

35.5M

Call Options Held

64.8K

Put Options Held

91.3K

View Full List

About Inhibrx, Inc.

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $553M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

More about INBX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.

Account

Virtus ETF Advisers LLC Inhibrx, Inc. Transaction History